Dantrolene-Associated Hepatic Injury

A case of drug-induced hepatic injury associated with sitagliptin.

A 58-year-old man with a 10-year history of type II diabetes mellitus presented with progressive jaundice that began three days before admission. Thorough history-taking revealed that the patient had started on a new medication, sitagliptin, one month previously for the treatment of diabetes mellitus. Laboratory investigations showed severe liver dysfunction. Ultrasonography detected no extrahe...

Hepatic ischemia-reperfusion injury.

24 Interferon regulatory factor-1 (IRF1) is a nuclear transcription factor that induces inflammatory 25 cytokine mediators and contributes to hepatic ischemia-reperfusion injury (I/R). Currently, no 26 strategies to mitigate IRF1-mediated liver damage exist. Interferon regulatory factor 2 (IRF2) is a 27 structurally similar endogenous protein that competes with IRF1 for DNA binding sites in IRF...

Dantrolene and lymphocytic lymphoma.

A patient is reported who was on prolonged treatment with dantrolene for spastic paraplegia; he developed a malignant lymphoma which led to his death.

Hepatitis from dantrolene sodium.

The clinical course and histological changes in the liver during a presumed adverse reaction to the drug dantrolene sodium are described in four patients. After a typical prodrome one developed a moderately severe hepatitis-like illness. Another also had a prodrome but never became jaundiced. In the other two, abnormal liver function tests were detected on routine screening. In each case liver ...

Hepatic injury caused by mianserin.